A blood test to detect circulating tumor DNA accurately predicted recurrence of HPV-driven oropharyngeal cancer after treatment, according to research presented at Multidisciplinary Head and Neck Cancers Symposium.
A blood test was able to accurately predict disease recurrence using circulating tumor tissue modified viral (TTMV)–human papillomavirus (HPV) DNA among patients treated for HPV-driven oropharyngeal squamous cell carcinoma, according to research presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.
A large, multi-institutional study demonstrates that a blood test to detect circulating tumor DNA can accurately predict recurrence of human papillomavirus (HPV)-driven oropharyngeal cancer following treatment.
A saliva-based diagnostic test that can detect HPV-related head and neck cancer has the potential to catch the disease earlier and even serve as a standard screening method, which the medical community currently lacks.
An experimental blood test accurately detected HPV-linked head and neck cancer recurrence and confirmed when patients remained cancer-free, according to findings from a study led by University of North Carolina Lineberger Comprehensive Cancer Center researchers.
Newswise — Using a new blood test that’s in development, University of North Carolina Lineberger Comprehensive Cancer Center researchers identified characteristics that could be used to personalize treatment for patients with a type of head and neck cancer linked to HPV infection.
San Antonio, Texas—A biomarker test that detects minute traces of cancer-specific DNA has been shown to determine whether patients with human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma are free from cancer following radiation therapy.
A novel liquid biopsy test showed compelling specificity and sensitivity in detecting HPV DNA among patients who underwent chemoradiotherapy for HPV-associated oropharyngeal squamous cell carcinoma, according to findings presented at the American Society for Radiation Oncology Annual Meeting.
CHAPEL HILL – A new blood test developed by University of North Carolina Lineberger Comprehensive Cancer Center researchers shows promise for tracking HPV-linked head and neck cancer patients to ensure they remain cancer-free after treatment.
